Kiadis Pharma
AMSTERDAM, January 4, 2011 - Kiadis Pharma, a biopharmaceutical company based in The Netherlands,
announced that it has entered into a licensing agreement with Hospira, Inc.
AMSTERDAM, July 8, 2010 - Biopharmaceutical Company Kiadis Pharma announced today that it has
received approval for its Investigational New Drug (IND) application with the
US Food and Drug Administration (FDA) to start the pivotal clinical study for
its product ATIR(TM) in the United States.
AMSTERDAM, April 28, 2010 - Kiadis Pharma today provided an update on its cell therapy product
ATIR(TM) developed for mismatched bone marrow transplants.
AMSTERDAM, November 30 - Biopharmaceutical company Kiadis Pharma announces today that the first
patients have been enrolled in its multinational registration clinical trial
with ATIR(TM).
AMSTERDAM - ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium
Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations.
